Varicella-zoster virus (VZV) is responsible for two distinct clinical conditions: chickenpox (varicella) and shingles (herpes zoster). While chickenpox represents the primary infection, VZV establishes lifelong latency in the sensory nervous system and can reactivate years or decades later as shingles. Safe, effective vaccines are available to prevent both diseases and minimize severe complications.
Understanding the core clinical differences between primary VZV infection and viral reactivation helps guide appropriate vaccination and clinical management.
| Clinical Feature | Chickenpox (Primary Infection) | Shingles (VZV Reactivation) |
|---|---|---|
| Pathophysiology | Initial VZV exposure and systemic dissemination. | Reactivation of latent VZV residing in sensory nerve ganglia. |
| Transmission | Respiratory droplets & direct blister fluid contact. Highly contagious. | Direct fluid contact from blisters only (transmits VZV as primary chickenpox to non-immune hosts). |
| Clinical Presentation | Generalized rash (300–500 pruritic vesicular lesions), fever, fatigue, body aches. | Unilateral, dermatomal painful vesicular rash preceded by prodromal burning/tingling. |
| Primary Complications | Secondary bacterial skin infections, VZV pneumonia, sepsis, encephalitis. | Postherpetic neuralgia (PHN), ophthalmic shingles (vision loss), facial paralysis, encephalitis. |
While primary chickenpox is generally self-limiting in healthy children, specific groups face heightened morbidity and mortality:
| Post-Exposure Window | Prophylactic Measure & Expected Efficacy |
|---|---|
| Within 3 Days | Varicella vaccine administration (>90% effective at preventing disease). |
| Within 5 Days | Varicella vaccine administration (~70% effective at preventing disease, highly effective against severe illness). |
| High-Risk / Vaccine Contraindicated | Varicella-Zoster Immune Globulin (VZIG) for non-immune individuals unable to receive live vaccines (e.g., pregnant patients, immunocompromised). |
| Vaccine | Type | Target Population | Dosing & Administration Schedule |
|---|---|---|---|
| Varicella Vaccine | Live Attenuated | Routine pediatric care; non-immune adults | • Pediatric: Dose 1 at 12–15 mos; Dose 2 at 4–6 yrs. • Adult/Catch-up: 2 doses given 4–8 weeks apart. |
| Shingrix (Preferred) | Recombinant (Non-Live) | Adults ≥50 years; prior Zostavax/shingles recipients | • 2-dose series given 2–6 months apart. • If post-shingles infection: delay until acute rash resolves (~8 weeks). |
| Zostavax (Legacy) | Live Attenuated | Adults ≥60 years (rarely used, lower efficacy) | • Single dose (re-vaccination with Shingrix recommended). |
Live attenuated vaccines trigger robust immune responses but carry significant risks for specific vulnerable patient populations.
Varicella-zoster virus causes primary chickenpox before settling into sensory nerve latency, where it can reactivate as shingles. Routine childhood varicella vaccination and adult recombinant immunization with Shingrix (2 doses) significantly reduce primary disease, painful reactivation, and severe complications like postherpetic neuralgia.
